wxk001

Walter K. Kraft, MD

Contact Dr. Kraft

132 South Tenth Street
1170 Main Building
Philadelphia, PA 19107

(215) 955-9077
(215) 955-5681 fax

Most Recent Peer-reviewed Publications

  1. Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome
  2. Longitudinal evaluation of azithromycin and cytokine concentrations in amniotic fluid following one-time oral dosing in pregnancy
  3. Seeking Similarities Rather Than Differences With Adults to Aid in Therapeutic Advancement for Children
  4. Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults
  5. Intraperitoneal pharmacokinetics of vancomycin in patients on automated peritoneal dialysis
  6. Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers
  7. Neonatal opioid withdrawal syndrome: a review of the science and a look toward the use of buprenorphine for affected infants
  8. Stability-indicating lc-ms method for determination of stability of extemporaneously compounded buprenorphine oral syringes for neonatal abstinence syndrome
  9. Twice-Daily Doravirine Overcomes the Interaction Effect from Once-Weekly Rifapentine and Isoniazid in Healthy Volunteers
  10. Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy
  11. Development of an abbreviated symptom score for the neonatal abstinence syndrome
  12. Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males
  13. Simultaneous quantitative LC–MS method of ketamine, midazolam and their metabolites (dehydronorketamine, norketamine and 1hydroxymidazolam) for its application in patients on extracorporeal membrane oxygenation (ECMO) therapy
  14. Is Maternal Methadone Dose Associated with the Severity of Neonatal Abstinence Syndrome?
  15. Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil
  16. Pharmacokinetics of vaginal progesterone in pregnancy
  17. Drug interactions between direct-acting oral anticoagulants and calcineurin inhibitors during solid organ transplantation: considerations for therapy
  18. Could Postnatal Age–Related Uridine Diphosphate Glucuronic Acid Be a Rate-Limiting Factor in the Metabolism of Morphine During the First Week of Life?
  19. Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome
  20. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects
  21. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients
  22. Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS)
  23. Incorporation of Quality and Safety Principles in Maintenance of Certification: A Qualitative Analysis of American Board of Medical Specialties Member Boards
  24. No meaningful drug interactions with doravirine, lamivudine and tenofovir disoproxil fumarate coadministration
  25. Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects (Clinical Drug Investigation, (2019), 10.1007/s40261-019-00764-x)